EV-Based Liquid Biopsy Market, By Biomarker Type, By Sample Type, By Application, By End-user, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.
The EV-based liquid biopsy market focuses on the use of extracellular vehicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry biological information, like RNA, DNA, proteins, and lipids, that reflects the state of their originating cells. This makes them valuable for detecting and monitoring diseases, especially cancers. Unlike traditional biopsies, EV-based liquid biopsies reduce patient discomfort and enable real-time tracking of disease progression. They are also advantageous for detecting tumors that are difficult to access or monitor using conventional methods.
Growing interest in precision medicine, early disease detection, and less invasive diagnostics is driving the adoption of this technology. Additionally, EVs are more stable in circulation compared to other biomarkers, which enhances their reliability. The market is expanding due to ongoing research, improved isolation techniques, and broader clinical applications. Despite some challenges, including a lack of standardization and regulatory clarity, EV-based liquid biopsy is emerging as a promising tool in modern diagnostics.
EV-Based Liquid Biopsy Market- Market Dynamics

Rising hospital-acquired infection control protocols drive demand for needle destroyers.
A key niche driver for the EV-based liquid biopsy market is the growing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be painful, risky, and not always feasible, especially for tumors in inaccessible locations. EVs, released by cancer cells into body fluids, carry genetic and proteomic information that mirrors the tumor’s state. This enables clinicians to track cancer progression, therapeutic response, or recurrence with simple fluid samples like blood.
The ability to perform serial sampling offers real-time monitoring without subjecting patients to repeated invasive procedures. Additionally, EVs are more stable in circulation than other biomarkers like cell-free DNA, improving result reliability. As oncology shifts toward personalized and precision-based approaches, EV-based biopsies are becoming a valuable tool for tailoring treatments. Their role is particularly significant in cases where tissue biopsy is not possible due to the patient’s health or tumor location. This rising clinical demand continues to propel innovation and investment in EV-based diagnostics.
EV-Based Liquid Biopsy Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.5% over the forecast period (2025-2032)
Based on Biomarker Type segmentation, microRNA (miRNA) and messenger RNA (mRNA), were predicted to show maximum market share in the year 2024
Based on Sample Type segmentation, Blood was the leading Sample Type in 2024
Based on Application segmentation, Cancer diagnostics was the leading Application in 2024
Based on region, North America was the leading revenue generator in 2024
EV-Based Liquid Biopsy Market- Segmentation Analysis:

The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.
The market is divided into four categories based on Biomarker Type. Proteins, RNA (miRNA, mRNA, etc.), DNA, Lipids, Others. Among the biomarker types in the EV-based liquid biopsy market, RNA, including microRNA (miRNA) and messenger RNA (mRNA), emerges as the most dominant segment. This prominence is due to the critical role RNA plays in reflecting the genetic activity of originating cells, especially cancer cells. EVs carry stable RNA molecules that provide valuable insights into gene expression patterns, enabling early disease detection and monitoring.
Compared to other biomolecules, RNA biomarkers offer high specificity and sensitivity, which are essential for accurate diagnosis and prognosis. miRNAs, in particular, regulate various cellular processes and have been linked to tumor progression, making them powerful indicators in liquid biopsies. Additionally, advances in RNA sequencing and analysis technologies have improved the ability to detect and quantify EV-associated RNAs reliably. The growing focus on personalized medicine further supports the use of RNA biomarkers, as they help tailor treatments based on molecular profiles. Despite challenges in isolating pure RNA from EVs, ongoing research is overcoming these obstacles, cementing RNA’s position as a key driver in this market.
The market is divided into five categories based on Application: Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Cancer diagnostics is the most dominant Sample Type segment in the EV-based liquid biopsy market. This dominance stems from the critical need for early, accurate, and minimally invasive methods to detect and monitor cancer. Extracellular vesicles released by tumor cells carry molecular signatures such as proteins, RNA, and DNA that provide real-time information about tumor presence, progression, and response to treatment. Unlike traditional tissue biopsies, EV-based liquid biopsies allow for continuous monitoring through simple blood or body fluid samples, reducing patient discomfort and enabling earlier intervention.
The rising global cancer burden and increasing emphasis on personalized medicine have further driven the adoption of EV-based diagnostics in oncology. Additionally, these liquid biopsies help detect tumors that are difficult to access or monitor through conventional methods. Research and clinical trials continue to validate the efficacy of EV biomarkers in cancer detection, making this Sample Type the primary growth driver for the market. While other Sample Types like infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the focal point of EV-based liquid biopsy development and commercialization.
EV-Based Liquid Biopsy Market- Geographical Insights

In North America, the EV-based liquid biopsy market is experiencing strong momentum due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. The region benefits from a robust research ecosystem supported by academic institutions, biotech companies, and government funding initiatives focused on cancer diagnostics. There is a growing awareness among healthcare professionals about the clinical value of extracellular vesicles in non-invasive disease detection and monitoring. The integration of EV-based tests into clinical practice is facilitated by the presence of well-established regulatory frameworks and ongoing clinical trials.
The United States is at the forefront of the EV-based liquid biopsy market, driven by its advanced healthcare infrastructure and strong emphasis on early cancer detection. The country's robust research ecosystem, encompassing leading academic institutions and bioEnd-user firms, fosters continuous innovation in diagnostic technologies. A growing preference for non-invasive diagnostic methods among clinicians and patients has accelerated the adoption of EV-based liquid biopsies, which offer real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these emerging technologies, ensuring safety and efficacy standards are met. However, challenges persist, including the need for standardized protocols for EV isolation and analysis.
EV-Based Liquid Biopsy Market- Competitive Landscape:

The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established bioend-user firms and innovative startups focused on extracellular vesicle technologies. Companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen are prominent players, leveraging their strong research capabilities and global reach to advance EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant strides through technological innovations in EV detection and characterization. Meanwhile, System Biosciences (SBI), Miltenyi Biotec, and AMSBIO are contributing specialized EV isolation and analysis kits.
Emerging companies like Exosomics S.p.A, Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms tailored for oncology and personalized medicine. The market is highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing a key role in shaping competitive positioning. As regulatory pathways become clearer, these companies are expected to expand their presence in clinical settings.

Recent Developments:

In October 2024, QIAGEN expanded its automated liquid biopsy portfolio to enhance oncology, prenatal care, and organ transplant applications. The new ccfDNA Kit upgrade with a urine protocol for EZ1 and 2 instruments is designed to improve liquid biopsy workflows for cancer research. The QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for downstream applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Exosome Diagnostics
Bio-Techne Corporation
Thermo Fisher Scientific
NanoView Biosciences
System Biosciences (SBI)
Qiagen
Norgen Biotek Corp.
BioVision Inc.
Miltenyi Biotec
Creative Biolabs
AMSBIO
Exosomics S.p.A
NX Pharmagen
VivaZome Therapeutics
Aethlon Medical
Evox Therapeutics
Capricor Therapeutics
Codiak BioSciences
Anjarium Biosciences
HansaBioMed Life Sciences

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

Proteins
RNA (miRNA, mRNA, etc.)
DNA
Lipids
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

Blood
Urine
Saliva
Cerebrospinal Fluid
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Cancer Diagnostics
Infectious Diseases
Neurological Disorders
Cardiovascular Diseases
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Research Institutes
Diagnostic Laboratories
Biopharmaceutical Companies
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more